Next 10 |
home / stock / prn:cc / prn:cc news
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, w...
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, t...
2024-03-07 23:35:04 ET Profound Medical Corp. (PROF) Q4 2023 Earnings Conference Call March 07, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Arun Menawat – Chief Executive Officer Rashed Dewan – Chief Financial Off...
2024-03-07 17:14:10 ET More on Profound Medical Profound Medical lays out Q4 and FY 2024 preliminary numbers Profound Medical sells 2.67M shares at $7.50 in public offering Seeking Alpha’s Quant Rating on Profound Medical Historical earnings data for P...
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, t...
Taseko Mines Limited (TKO:CA) is expected to report $0.09 for Q4 2023 Purepoint Uranium Group Inc. (PTU:CA) is expected to report for quarter end 2023-12-31 Perpetual Energy Inc. (PMT:CA) is expected to report $-0.02 for Q4 2023 Park Lawn Corporation (PLC:CA) is expected to report $0....
TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, t...
TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, to...
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, wi...
2024-01-16 16:35:19 ET More on Profound Medical Profound Medical lays out Q4 and FY 2024 preliminary numbers Profound Medical sells 2.67M shares at $7.50 in public offering For further details see: Profound Medical announces $2.94M non-brokered private placement
News, Short Squeeze, Breakout and More Instantly...
Profound Medical Corp. Company Name:
PRN:CC Stock Symbol:
TSXC Market:
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, w...
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, t...
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, t...